Theres growing evidence suggesting a positive role of GLP-1 agonists in managing polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD), providing new avenues for addressing these difficult-to-treat disorders
It remains an investigational medicine, currently being evaluated in ongoing clinical trials to establish its efficacy, safety, and optimal dosing in larger and more diverse patient populations
Weight loss becomes measurable
Yes, a generic version of the brand name Lamictal is available
Physical signs that a reconstituted injectable solution may have degraded include: Visible particulate matter cloudiness, floating particles, or sediment that does not clear upon gentle swirling Discolouration any yellowing, browning, or change from the expected clear, colourless appearance Change in consistency a gel-like or unusually viscous texture may suggest protein aggregation Any unusual odour upon opening, which may indicate contamination Importantly, chemical degradation including oxidation, deamidation, or hydrolysis of peptide bonds can occur without any visible change to the solution (EMA/ICH Q5C guideline on stability of biotechnological products)
